On this page
Anophthalmia/microphthalmia (OTX2)
These rare eye conditions are present from birth and can significantly affect vision, ranging from severe visual impairment to complete blindness. They primarily impact infants and children and are often associated with changes in the OTX2 gene.
Overview
Anophthalmia and microphthalmia are congenital conditions affecting eye development. Anophthalmia describes the complete absence of eye tissue within the orbit (eye socket), while microphthalmia refers to a globe (eye) that is abnormally small and underdeveloped [PMID:33671253]. These conditions can affect one eye (unilateral) or both eyes (bilateral) and vary widely in severity. They are considered rare, with an estimated combined prevalence that is not precisely established but is thought to affect approximately 1 in 7,000 to 1 in 10,000 live births [PMID:24765961].
These conditions are typically identified at birth or shortly after, and their presence can have a significant impact on an individual's visual capabilities and overall development. The underlying causes are diverse, encompassing genetic factors, environmental exposures, or a combination of both. Genetic forms, such as those involving the OTX2 gene, are increasingly recognised and often lead to these developmental abnormalities affecting the eyes.
Symptoms & clinical features
The primary clinical features of anophthalmia and microphthalmia relate directly to the size and presence of the eye. In anophthalmia, the eye socket may appear empty, while in microphthalmia, the affected eye is visibly smaller than typical. Depending on the extent of eye development, vision can range from severely impaired to completely absent. If microphthalmia is very subtle, it might not be immediately obvious but could still significantly affect vision [PMID:24765961].
Individuals born with anophthalmia or severe microphthalmia may also have associated facial asymmetry or other developmental differences. When both eyes are affected, children will typically require early support for visual impairment and development. The impact on daily life really depends on whether one or both eyes are involved, and the degree of vision present in any affected eye.
Video: Genetics 101
Affected organs
These conditions primarily affect the eyes. Specifically, anophthalmia involves the complete absence of an eye, while microphthalmia signifies an abnormally small eye. In some cases, the structures within the eye, such as the lens, retina, or optic nerve, may also be underdeveloped or malformed. When OTX2 gene changes are the cause, other brain structures, particularly the pituitary gland and areas involving brain development, can sometimes be affected. This can lead to a range of additional clinical features, including hormone deficiencies or developmental delay, though these are not always present.
Risks & severity
The severity of anophthalmia and microphthalmia can vary significantly. Anophthalmia represents the most severe end of the spectrum, with complete absence of visual function in the affected eye(s). Microphthalmia can range from mild reductions in eye size with some functional vision, to severe forms where the eye is extremely underdeveloped and sightless. The lifetime risks associated with these conditions include lifelong visual impairment or blindness, which can necessitate significant support for education and daily living.
Approximately 7.9% of all cases of isolated anophthalmia/microphthalmia are attributed to OTX2 variations [PMID:29606821]. Early diagnosis and intervention are crucial for managing the condition and supporting development. The potential for associated health issues, particularly if other organs or brain structures are affected, adds to the complexity and severity for some individuals.
Genetic causes
Anophthalmia and microphthalmia can arise from genetic factors, and changes in the OTX2 gene are a known cause. The OTX2 gene provides instructions for making a protein called orthodenticle homeobox 2. This protein is a transcription factor, meaning it plays a critical role in controlling the activity of other genes. Specifically, the OTX2 protein is essential for the early development of the eye and certain brain structures, including the forebrain and midbrain [PMID:29606821].
Pathogenic variants (changes) in OTX2 can disrupt the normal function of this protein. This disruption can interfere with the complex processes required for proper eye formation during embryonic development, leading to anophthalmia or microphthalmia. The type of OTX2 change can influence the severity and presentation of the condition, sometimes affecting other developmental processes beyond the eye.
- OTX2 orthodenticle homeobox 2
Inheritance pattern
Anophthalmia/microphthalmia due to OTX2 changes is inherited in an autosomal dominant pattern. This means that only one copy of the altered OTX2 gene in each cell is sufficient to cause the condition. In many cases, the genetic change occurs spontaneously (de novo) in the affected individual and is not inherited from a parent. However, an affected parent has a 50% chance of passing on the altered gene to each of their children, regardless of the child's sex.
For families where an OTX2 variant is identified, genetic counselling is available to discuss the inheritance pattern, recurrence risks, and options for family planning. Even if parents are unaffected, there's a small chance of germline mosaicism, where some reproductive cells carry the variant, leading to a low recurrence risk.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of anophthalmia or microphthalmia is typically made through clinical examination shortly after birth. Imaging techniques, such as ultrasound or MRI, are often used to assess the extent of eye underdevelopment and to check for any associated brain abnormalities.
Genetic testing is an important step to identify the underlying cause, especially when a genetic aetiology is suspected, such as in cases with bilateral involvement or additional developmental differences. For investigation of these eye conditions, an NHS Genomic Medicine Service (GMS) 'R code' such as R94 (anophthalmia, microphthalmia, coloboma) may be relevant. Referral to a clinical geneticist team via your GP or paediatrician can facilitate access to appropriate genetic testing and counselling.
Management & lifestyle
Due to the unique and complex nature of anophthalmia and microphthalmia, management is highly individualised and multidisciplinary. This typically involves a team of specialists including ophthalmologists, paediatricians, geneticists, and prosthetists. For anophthalmia or severe microphthalmia, prosthetic eyes or conformers may be used to help ensure proper facial and orbital bone development and for cosmetic appearance, beginning in infancy.
Support for visual impairment is a key aspect of care. This can include early intervention programmes, educational support, and access to assistive technologies. For individuals with OTX2-related conditions, regular screening for associated brain and pituitary gland issues may be recommended, as these can sometimes lead to hormone deficiencies that require treatment. The NHS provides a clear pathway for ongoing care, including regular follow-up appointments and access to specialist services.
UK care pathway
In the UK, individuals suspected of having anophthalmia or microphthalmia, particularly with a possible genetic cause, can access care through the NHS Genomic Medicine Service (GMS). This typically begins with a referral from a GP or another specialist, such as a paediatrician or ophthalmologist, to a clinical genetics service. Genetic counsellors within these services play a vital role in explaining genetic test results, inheritance patterns, and potential implications for the wider family. Relevant GMS 'R codes' are used to guide diagnostic genomic testing, ensuring appropriate tests are performed.
Frequently asked questions
Will my child be able to see if they have anophthalmia or microphthalmia?
With anophthalmia, there is no eye tissue, so vision is impossible in the affected eye(s). For microphthalmia, vision can range from severely limited to completely absent, depending on how underdeveloped the eye is. Each case is unique, and specialists will assess the potential for vision.
What kind of support is available for children with these conditions?
Comprehensive support is available, including early intervention programmes for visual impairment, educational support, and access to assistive devices. Prosthetic eyes can be fitted from a young age to aid facial development and for cosmetic purposes. A multidisciplinary clinical team will work with families to provide tailored care.
If I have a child with OTX2-related anophthalmia/microphthalmia, what are the chances of having another affected child?
If the OTX2 change occurred spontaneously (de novo) in your child and neither parent carries the change, the chance of it happening again is very low. However, if one parent carries the change, or if a very rare situation called germline mosaicism is present, the risk can be higher. Genetic counselling can provide a precise risk assessment for your family.
Are there other health issues associated with OTX2-related anophthalmia/microphthalmia?
Sometimes, yes. The OTX2 gene is important for both eye and brain development. In some individuals, changes in OTX2 can also lead to other issues such as pituitary gland dysfunction (affecting hormones) or developmental differences. Regular medical check-ups will help monitor for these potential complications.
How is the condition managed as my child grows?
Management adapts as a child grows. This includes regular ophthalmology appointments, adjustments to prosthetic eyes as needed, and ongoing support for visual impairment. If there are any associated medical conditions, these will also be managed by relevant specialists to ensure comprehensive care throughout childhood and into adulthood.